Diagnostic potential of hypermethylation of the cysteine dioxygenase 1 gene (
            
              CDO
              1
            
            ) promoter
            DNA
            in pancreatic cancer

Abstract PurposeThe aim of this study was to explore the diagnostic potential of a panel of five hypermethylated gene promoters in bladder cancer. Individuals with primary BCa and control individuals matching the gender, age and smoking status of the cancer patients were recruited. DNA methylation was assessed for the gene promoters of RASSF1, RARβ, DAPK, hTERT and APC in urine samples collected by spontaneous urination. Fifty patients and 35 healthy controls were recruited, with average age of 70.26 years and average smoking status of 44.78 pack-years. In the BCa group, DNA methylation was detected in 27(61.4%) samples. RASSF1 was methylated in 52.2% of samples. Only 3(13.6%) samples from the control group were methylated, all in the RASSF1 gene promoter. The specificity and sensitivity of this panel of genes to diagnose BCa was 86% and 61% respectively. The RASSF1 gene could diagnose BCa with specificity 86.4% and sensitivity 52.3%. Promoter DNA methylation of this panel of five genes could be further investigated as urine biomarker for the diagnosis of BCa. The RASSF1 could be a single candidate biomarker for predicting BCa patients versus controls. Studies are required in order to develop a geographically adjusted diagnostic biomarker for BCa.Trial registration: ACTRN12620000258954

Download Full-text

Abstract 665: Promoter DNA methylation is associated with metastatic properties of pancreatic cancer.

10.1158/1538-7445.am2013-665 ◽

2013 ◽

Author(s):

Huey-Jen L. Lin ◽

Zhengang Peng ◽

Amanda Fisher ◽

Jennifer C. Weber ◽

Ying-Wei Li

Keyword(s):

Pancreatic Cancer ◽

Dna Methylation ◽

Promoter Dna Methylation ◽

Promoter Dna

Download Full-text

Promoter DNA Hypermethylation of the Cysteine Dioxygenase 1 (CDO1) Gene in Intraductal Papillary Mucinous Neoplasm (IPMN)

Annals of Surgical Oncology ◽

10.1245/s10434-020-08291-2 ◽

2020 ◽

Vol 27 (10) ◽

pp. 4007-4016 ◽

Cited By ~ 1

Author(s):

Yoshiki Fujiyama ◽

Yusuke Kumamoto ◽

Nobuyuki Nishizawa ◽

Shuji Nakamoto ◽

Hiroki Harada ◽

...

Keyword(s):

Intraductal Papillary Mucinous Neoplasm ◽

Cysteine Dioxygenase ◽

Dna Hypermethylation ◽

Mucinous Neoplasm ◽

Promoter Dna

Download Full-text

Predictive Significance of Promoter DNA Methylation of Cysteine Dioxygenase Type 1 (CDO1) in Metachronous Gastric Cancer

Journal of Gastric Cancer ◽

10.5230/jgc.2021.21.e35 ◽

2021 ◽

Vol 21 ◽

Author(s):

Yo Kubota ◽

Satoshi Tanabe ◽

Mizutomo Azuma ◽

Kazue Horio ◽

Yoshiki Fujiyama ◽

...

Keyword(s):

Gastric Cancer ◽

Dna Methylation ◽

Cysteine Dioxygenase ◽

Promoter Dna Methylation ◽

Metachronous Gastric Cancer ◽

Promoter Dna

Download Full-text

Diagnostic potential of mucins in pancreatic juice for pancreatic cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.4_suppl.222 ◽

2016 ◽

Vol 34 (4_suppl) ◽

pp. 222-222

Author(s):

Asish Patel ◽

Sukhwinder Kaur ◽

Lynette Smith ◽

Chandrakanth Are ◽

Surinder Batra

Keyword(s):

Pancreatic Cancer ◽

Pancreatic Juice ◽

Sandwich Elisa ◽

Pairwise Comparison ◽

Individual Performance ◽

Diagnostic Potential ◽

Wilcoxon Rank Sum Test ◽

Diagnostic Panel ◽

Curve Modeling ◽

Potential Methods

222 Background: Pancreatic juice remains an underutilized resource for diagnosing pancreatic cancer. Mucins are high molecular weight glycoproteins differentially upregulated in pancreatic cancer, and we hypothesize that their profile in pancreatic juice may have diagnostic potential. Methods: Pancreatic juice was obtained during endoscopy from non-healthy non-pancreatic control (NHPC, n = 57), chronic pancreatitis (CP, n = 23), and pancreatic cancer (PC, n = 23) patients. Sandwich ELISA was used to detect MUC1, MUC4, MUC5AC, CA125, and CA19-9. Kruskal-Wallis test and Wilcoxon rank sum test for group and pairwise comparison was done with p < 0.05 as significant. Logistic regression with ROC curve modeling of log transformed data was done for each biomarker individually and in combination to determine odds ratio (OR), sensitivity (SN), and specificity (SP) for PC. Results: PC vs NHPC: MUC5AC had the best individual performance for diagnosing PC with an OR = 2.78 (95% CI = 1.51-5.13), AUC = 0.81, and optimal SN/SP of 0.83 and 0.67, respectively. CA125 was increased in PC with an OR = 2.31 (95% CI = 1.4-4.0), AUC = 0.73, and optimal SN/SP of 0.88 and 0.67. CA19-9 was increased in PC with an OR = 1.5 (95% CI = 1.2-1.8), AUC = 0.76, and optimal SN/SP of 0.73 and 0.70. A combination of MUC1, MUC5AC, CA125, and CA19-9 outperformed all individual markers and had the largest AUC (0.89) with optimal SN/SP of 0.84 and 0.79. PC vs CP: MUC1 concentration in PC was significantly less than CP with an OR = 0.21 (95%CI = 0.088-0.49), AUC = 0.82, and optimal SN/SP of 0.87 and 0.78. PC vs NHPC+CP: MUC1 was decreased significantly in PC with an OR = 0.65 (95% CI = 0.44-0.96), AUC = 0.69, and optimal SN/SP of 0.87 and 0.63. CA125 was increased in PC with an OR = 1.64 (95%CI = 1.1-2.4), AUC = 0.66, and optimal SN/SP of 0.67 and 0.64. CA19-9 was increased in PC with an OR = 1.32 (95%CI = 1.1-1.6), AUC = 0.68, and optimal SN/SP of 0.63 and 0.67. A combination of MUC1, MUC5AC, CA125, and CA19-9 had an AUC = 0.86 with optimal SN/SP of 0.87 and 0.77 for PC. Conclusions: MUC1, MUC5AC, CA125, and CA19-9 combination provides a significantly improved diagnostic panel compared to any individual marker in pancreatic juice for detecting malignancy.

Download Full-text